790 Thermo Fisher Scientific Inc. $TMO Shares Sold by Jacobs & Co. CA

Jacobs & Co. CA trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.9% in the 3rd quarter, Holdings Channel reports. The firm owned 15,386 shares of the medical research company’s stock after selling 790 shares during the quarter. Jacobs & Co. CA’s holdings in Thermo Fisher Scientific were worth $10,386,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $15,501,867,000. State Street Corp grew its stake in shares of Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after buying an additional 229,630 shares during the last quarter. Corient Private Wealth LP purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $382,547,000. Bank of New York Mellon Corp bought a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $1,974,561,000. Finally, Bank of America Corp DE bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at about $1,952,930,000. 89.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on TMO. Piper Sandler assumed coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an “overweight” rating on the stock. CLSA started coverage on Thermo Fisher Scientific in a research report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price objective on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Scotiabank started coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an “outperform” rating for the company. Finally, Royal Bank Of Canada lifted their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $634.86.

Insider Buying and Selling

In related news, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $658.23 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $694.33. The firm’s 50-day simple moving average is $627.39 and its two-hundred day simple moving average is $541.36. The stock has a market cap of $243.38 billion, a PE ratio of 35.41, a price-to-earnings-growth ratio of 2.73 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.